0.000518061508029884 -0.000235482503650032 -0.0019780530306599 -0.00226063203503975 0.00193095652992981 0.00372062355766963 0.00211934253284976 -0.000329675505109938
Sign Up Today X
Thanks for submitting the form.
Stockreport

ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia [Yahoo! Finance]

Gilead Sciences, Inc. (GILD)  More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
The studies will evaluate bempedoic acid alone and in combination with ezetimibe in pediatric patients with heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH). The phase III studies are expected to begin later in 2025. Esperion markets bempedoic acid as Nexletol and Nexlizet for treating elevated LDL-C (bad cholesterol) and cardiovascular risk reduction. Nexlizet is a combination of bempedoic acid and ezetimibe. Two separate phase III studies, namely — CLEAR Path 2 (in children with HeFH) and CLEAR Path 3 (in children with HoFH), will evaluate the safety and efficacy of bempedoic acid with and without ezetimibe in children with HeFH or HoFH and LDL-C =130 mg/dL who are on a protocol defined optimum dose of a statin. In the past year, shares of Esperion have plunged 29.3% compared with the industry's decline of 6.8%. Image Source: Zacks Investment Research Nexletol and Nexlizet are marketed as Nilemdo and Nustendi in ex-U.S. [Read more]
IMPACT SNAPSHOT EVENT TIME: GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
GILD alerts
from News Quantified
GILD
NEWS
GILD
Earnings
GILD
Analyst Actions
GILD
SEC Filings
Stockreport

ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia [Yahoo! Finance]

Gilead Sciences, Inc.  (GILD) 
More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
The studies will evaluate bempedoic acid alone and in combination with ezetimibe in pediatric patients with heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH). The phase III studies are expected to begin later in 2025. Esperion markets bempedoic acid as Nexletol and Nexlizet for treating elevated LDL-C (bad cholesterol) and cardiovascular risk reduction. Nexlizet is a combination of bempedoic acid and ezetimibe. Two separate phase III studies, namely — CLEAR Path 2 (in children with HeFH) and CLEAR Path 3 (in children with HoFH), will evaluate the safety and efficacy of bempedoic acid with and without ezetimibe in children with HeFH or HoFH and LDL-C =130 mg/dL who are on a protocol defined optimum dose of a statin. In the past year, shares of Esperion have plunged 29.3% compared with the industry's decline of 6.8%. Image Source: Zacks Investment Research Nexletol and Nexlizet are marketed as Nilemdo and Nustendi in ex-U.S. [Read more]
IMPACT SNAPSHOT
EVENT TIME:
GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS